FOR IMMEDIATE RELEASE
GO-Dx Corporation (Aust) Ltd Announces Listing on NSX
[Singapore, 11 July 2024] – GO-Dx Corporation Ltd (Aust) (Ticker: GD8), a leading innovator in diagnostic and health profiling technologies, is pleased to announce that its shares will be listed and begin trading on the National Stock Exchange (NSX) under the ticker symbol GD8 on July 16, 2024.
Founded with a commitment to revolutionizing diagnostic and precision medicine solutions, GO-Dx has rapidly emerged as a key player in the healthcare technology sector. The listing on NSX represents a significant milestone in the company’s journey, providing enhanced visibility and access to a broader investor base.
“We are excited to embark on this next chapter of growth and development as a publicly listed company on the NSX,” said Dr Lim Kah Meng, CEO of GO-Dx Corporation (Aust) Ltd. “This listing will enable us to further strengthen our position in the market, accelerate innovation, and deliver long-term value to our shareholders.”
The NSX listing underscores GO-Dx’s dedication to transparency, accountability, and shareholder value. The company remains committed to advancing its mission of delivering cutting-edge diagnostic and precision medicine solutions that improve and enhance patient outcomes globally.
About GO-Dx Corporation (Aust) Ltd:
GO-Dx Corporation (Aust) Ltd is a pioneering healthcare technology company specializing in advanced diagnostic and precision medicine solutions. With a focus on innovation and customer-centricity, GO-Dx is dedicated to enhancing diagnostic and health profiling accuracy and efficiency across diverse healthcare settings.
For detailed listing information, please visit GO-Dx Corporation (Aust) Ltd NSX Listing.